Drugs / BCG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05947890 | Jan 2024 → Apr 2027 expected | HIV infectious disease, tuberculosis | HIV Vaccine Trials Network | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05947890 ↗ |
| Modality | Vaccine | “The active substance in BCG vaccine is a freeze-dried powder containing live attenuated Mycobacterium bovis BCG, Danish strain 1331 and sodium glutamate as a stabilizer.” NCT05947890 ↗ |
| Route | Other | “Participants will receive BCG as a 0.1 mL intradermal (ID) injection, in the upper arm once at Week 0.” NCT05947890 ↗ |